243 related articles for article (PubMed ID: 19798644)
21. Natalizumab-associated central nervous system lymphoma?--another patient.
Matzke M; Schreiber S; Elolf E; Metz I; Mawrin C; Heinze HJ; Sailer M
Mult Scler; 2012 Nov; 18(11):1653-4. PubMed ID: 22383229
[No Abstract] [Full Text] [Related]
22. Tysabri raises alarm bells on drug class.
Sheridan C
Nat Biotechnol; 2005 Apr; 23(4):397-8. PubMed ID: 15815649
[No Abstract] [Full Text] [Related]
23. Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists.
Heesen C; Kleiter I; Nguyen F; Schäffler N; Kasper J; Köpke S; Gaissmaier W
Mult Scler; 2010 Dec; 16(12):1507-12. PubMed ID: 20826527
[TBL] [Abstract][Full Text] [Related]
24. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
Engelhardt B; Kappos L
Neurodegener Dis; 2008; 5(1):16-22. PubMed ID: 18075270
[TBL] [Abstract][Full Text] [Related]
25. [New drugs; natalizumab].
van Bronswijk H; Dubois EA; van Gerven JM; Cohen AF
Ned Tijdschr Geneeskd; 2008 Mar; 152(9):499-500. PubMed ID: 18389881
[TBL] [Abstract][Full Text] [Related]
26. Selective adhesion-molecule therapy and inflammatory bowel disease.
Chaudhuri A
N Engl J Med; 2006 Feb; 354(6):644-5; author reply 644-5. PubMed ID: 16467556
[No Abstract] [Full Text] [Related]
27. MS drug withdrawn from market.
FDA Consum; 2005; 39(3):3. PubMed ID: 16127808
[No Abstract] [Full Text] [Related]
28. MS drug back on market under restricted program.
FDA Consum; 2006; 40(4):7. PubMed ID: 17243280
[No Abstract] [Full Text] [Related]
29. Natalizumab for relapsing multiple sclerosis.
Jeffery DR
N Engl J Med; 2006 Jun; 354(22):2387-9; author reply 2387-9. PubMed ID: 16742008
[No Abstract] [Full Text] [Related]
30. Lessons for clinical trials from natalizumab in multiple sclerosis.
Chaudhuri A
BMJ; 2006 Feb; 332(7538):416-9. PubMed ID: 16484271
[TBL] [Abstract][Full Text] [Related]
31. Natalizumab and progressive multifocal leukoencephalopathy.
Adelman B; Sandrock A; Panzara MA
N Engl J Med; 2005 Jul; 353(4):432-3. PubMed ID: 15947083
[No Abstract] [Full Text] [Related]
32. Natalizumab for relapsing multiple sclerosis.
Meyer MA
N Engl J Med; 2006 Jun; 354(22):2387-9; author reply 2387-9. PubMed ID: 16742009
[No Abstract] [Full Text] [Related]
33. Third Tysabri adverse case hits drug class.
Sheridan C
Nat Rev Drug Discov; 2005 May; 4(5):357-8. PubMed ID: 15902765
[No Abstract] [Full Text] [Related]
34. Multiple sclerosis woes.
Nat Neurosci; 2005 Jul; 8(7):837. PubMed ID: 16136665
[No Abstract] [Full Text] [Related]
35. Tysabri back on market.
Sheridan C
Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111
[No Abstract] [Full Text] [Related]
36. PML risk and natalizumab: more questions than answers.
Ransohoff RM
Lancet Neurol; 2010 Mar; 9(3):231-3. PubMed ID: 20117056
[No Abstract] [Full Text] [Related]
37. [Progressive multifocal leukoencephalopathy after natalizumab therapy].
Schmitt C; Bensussan A
Med Sci (Paris); 2005 Oct; 21(10):797-8. PubMed ID: 16197890
[No Abstract] [Full Text] [Related]
38. Does the flap of a butterfly's wings in Brazil set off a tornado in Texas?--The JC Virus Story in multiple sclerosis.
Achiron A; Miron S; Shoenfeld Y
Isr Med Assoc J; 2005 May; 7(5):283-5. PubMed ID: 15909458
[No Abstract] [Full Text] [Related]
39. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.
Ko MY; Stefoski D; Balabanov R
Neurology; 2011 Sep; 77(10):1020; author reply 1020. PubMed ID: 21893676
[No Abstract] [Full Text] [Related]
40. The trials and tribulations of Tysabri.
Lancet Neurol; 2006 May; 5(5):373. PubMed ID: 16632299
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
